

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 November 2007 (08.11.2007)

PCT

(10) International Publication Number
WO 2007/126957 A3

(51) International Patent Classification:

C07D 213/74 (2006.01) C07D 401/10 (2006.01)
C07D 213/75 (2006.01) C07D 401/12 (2006.01)
C07D 213/81 (2006.01) C07D 401/14 (2006.01)
C07D 213/82 (2006.01) C07D 405/12 (2006.01)
C07D 237/20 (2006.01) C07D 413/10 (2006.01)
C07D 239/42 (2006.01) C07D 413/12 (2006.01)
C07D 263/48 (2006.01) A61K 31/44 (2006.01)
C07D 277/42 (2006.01)

(21) International Application Number:

PCT/US2007/007772

(22) International Filing Date: 28 March 2007 (28.03.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/787,859 31 March 2006 (31.03.2006) US

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): **NOVARTIS PHARMA GmbH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SERRANO-WU, Michael, H.** [US/US]; 4 Elizabeth Road, Belmont, MA 02478 (US). **KWAK, Young-Shin** [KR/US]; 58 Blossomcrest Road, Lexington, MA 02421 (US). **LIU, Wenming** [CN/US]; 14 Winterset Drive, Morris Plains, NJ 07950 (US).

(74) Agent: **MILSTEAD, Mark, W.**; Novartis, Corporate Intellectual Property, One Health Plaza Bldg. 104, East Hanover, NJ 07936 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report

(88) Date of publication of the international search report:

24 January 2008

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NEW COMPOUNDS

(57) Abstract: The present invention provides organic compounds of the following structure; A-L1-B-C-D-L2-E that are useful for treating or preventing conditions or disorders associated with DGAT1 activity in animals, particularly humans.



WO 2007/126957 A3